Clinical Trials Browser

Phase 2 × Neoplasms, Second Primary × Leucovorin × Clear all

NCT05217069 2025-04-16

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

Phase 2 Completed

Neoplasms, Second Primary

NCT04034173 2019-07-26

Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation

Phase 2 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms, Neoplasms, Second Primary